BIOLASE Reports 46% Revenue Growth In 2021 Third Quarter; Demand For Dental Lasers From New Customers Remains High And Continues To Fuel Growth

Expects Significant Revenue Growth Year-Over-Year in Fourth Quarter 2021 FOOTHILL RANCH, Calif., Nov. 10, 2021…

Expects Significant Revenue Growth Year-Over-Year in Fourth Quarter 2021

FOOTHILL RANCH, Calif., Nov. 10, 2021 /PRNewswire/ — BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced its financial results for its third quarter ended September 30, 2021 and provided fourth quarter 2021 revenue guidance.

BIOLASE Logo (PRNewsfoto/BIOLASE, Inc.)

2021 Third Quarter Operating Highlights (all comparisons are on a year-over-year basis unless specified otherwise):

  • Net revenue grew 46% to $9.5 million:

  • Net revenue was 10% higher than third quarter of 2019, which was the last pre-pandemic comparable period

  • Laser system sales increased 64%

  • Consumables and other revenue increased 21%

  • U.S. and international revenue increased 25% and 101%, respectively, as more dental practices were operating during the 2021 third quarter compared to the year-ago third quarter due to the COVID-19 pandemic

  • Gross margin was 51%, up 1,600 basis points, due to the higher year-over-year revenue, favorable revenue mix and higher average selling prices for products sold during the quarter

  • Maintained strong balance sheet, as cash and cash equivalents totaled $33.4 million at quarter end

“Our strong third quarter performance continues to reflect the rising demand for our industry-leading dental lasers,” commented John Beaver, President and Chief Executive Officer. “Our efforts to both educate and train dental specialists is leading to increased adoption across these large and largely untapped markets. In today’s environment, the fact that BIOLASE lasers provide increased safety to dentists and their patients is generating a high level of acceptance by dental practitioners – and we expect this to be a driving force for the foreseeable future. Our industry-leading dental lasers aim to provide a better standard of care for dental procedures and seek to ensure a safer experience while reducing the risk of future procedure and business disruptions by reducing aerosolization to mitigate the spread of infectious pathogens, such as COVID-19. Looking ahead, we expect significant year-over-year improvement across our key performance metrics, including revenue and gross margin in the fourth quarter as we continue to gain momentum with new customers and dental specialists.”

2021 Third Quarter Financial Results

Net revenue for the third quarter of 2021 was $9.5 million, an increase of 46% compared to net revenue of $6.5 million for the third quarter of 2020, which was impacted by the COVID-19 pandemic as many dental practitioners were forced to suspend procedures. U.S. laser revenue was $3.4 million for the third quarter of 2021, up 25% when compared to U.S. laser revenue of $2.7 million for the third quarter of 2020. U.S. consumables and other revenue for the third quarter of 2021, which consists of revenue from consumable products such as disposable tips, increased 26% compared to the third quarter of 2020. Outside the U.S., laser revenue increased 168% to $2.7 million for the third quarter of 2021, compared to $1.0 million for the third quarter of 2020, and consumables and other revenue increased 13% year over year as recovery from the pandemic improved internationally.

Gross margin for the third quarter of 2021 was 51%, compared to 35% for the third quarter of 2020. The higher gross margin reflects the impact of the increase in revenues and increased average selling prices for products sold during the third quarter of 2021. Total operating expenses were $7.5 million for the third quarter of 2021, compared to $5.9 million for the third quarter of 2020. Operating loss for the third quarter of 2021, was $2.7 million, compared to an operating loss of $3.7 million in the third quarter of 2020. Net loss for the third quarter of 2021 was $3.3 million, or $0.02 per share, compared to a net income of $12,000, or less than $0.01 per share, for the third quarter of 2020.

Adjusted EBITDA loss for the third quarter of 2021 was $2.5 million, or $0.02 per share, compared to Adjusted EBITDA loss of $2.5 million, or $0.03 per share, for the third quarter of 2020.

Cash and cash equivalents totaled $33.4 million as of September 30, 2021. Due to the proactive and strategic decisions the Company took over the past year, BIOLASE’s balance sheet remains historically strong, and is providing it with the resources the Company believes it needs to execute its growth strategies for several years without having to access the capital markets.

2021 Fourth Quarter Revenue Guidance

The Company continues to experience high demand for its dental lasers and is currently forecasting revenue for the fourth quarter ending December 31, 2021 to be above the pre-pandemic revenue in the fourth quarter of 2019 of $10.2 million.

Conference Call Information

BIOLASE, Inc. will host a conference call today at 4:30 p.m. Eastern Time to discuss its operating results for the third quarter ended September 30, 2021, and to answer questions. For both “listen-only” participants and those participants who wish to take part in the question-and-answer portion of the call, the dial-in number in the U.S./Canada is (800) 367-2403. For international participants outside the U.S./Canada, the dial-in number is (334) 777-6978. For all callers, refer to the Conference ID 3599686. To access the live webcast, visit the Investor Relations section of the BIOLASE website at www.biolase.com and see “Investor Events”.

An audio archive of the webcast will be available on the Investor Relations section of the BIOLASE website.

About BIOLASE

BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. BIOLASE’s products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASE’s proprietary laser products incorporate approximately 271 patented and 40 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times. BIOLASE’s innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients. BIOLASE’s principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. BIOLASE has sold over 41,200 laser systems to date in over 80 countries around the world. Laser products under development address BIOLASE’s core dental market and other adjacent medical and consumer applications.

For updates and information on Waterlase iPlus®, Waterlase Express™, and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Instagram at www.instagram.com/waterlase_laserdentistry, and LinkedIn at www.linkedin.com/company/biolase.

BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE, Inc.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties, including statements regarding BIOLASE’s expected future revenue, gross margin and other key metrics; anticipated demand for BIOLASE’s products and anticipated driving forces such as demand; and anticipated cash needs. Forward-looking statements can be identified through the use of words such as may,” “might,” “will,” “intend,” “should,” “could,” “can,” “would,” “continue,” “expect,” “believe,” “anticipate,” “estimate,” “predict,” “outlook,” “forecast,” “guidance,” “potential,” “plan,” “seek,” and similar expressions and variations or the negatives of these terms or other comparable terminology. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE’s current expectations and speak only as of the date of this release. Actual results may differ materially from BIOLASE’s current expectations depending upon a number of factors. These factors include, among others, the coronavirus (COVID-19) and the effects of the pandemic and actions taken in connection therewith, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business, and those other risks and uncertainties that are described in the “Risk Factors” section of BIOLASE’s most recent annual report filed on Form 10-K and BIOLASE’s quarterly report for the second quarter of 2021 filed on Form 10-Q filed with the Securities and Exchange Commission. Except as required by law, BIOLASE does not undertake any responsibility to revise or update any forward-looking statements.

Tables to Follow

BIOLASE, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited, in thousands, except per share data)

Three Months Ended

Nine Months Ended

September 30,

September 30,

2021

2020

2021

2020

Net revenue

$

9,531

$

6,539

$

26,780

$

14,260

Cost of revenue

4,689

4,265

15,157

9,692

Gross profit

4,842

2,274

11,623

4,568

Operating expenses:

Sales and marketing

3,451

2,678

10,315

7,475

General and administrative

2,479

2,300

8,613

7,446

Engineering and development

1,540

963

4,506

2,644

Loss on patent litigation settlement

29

190

Total operating expenses

7,499

5,941

23,624

17,565

Loss from operations

(2,657)

(3,667)

(12,001)

(12,997)

Gain (Loss) on foreign currency transactions

(36)

53

(172)

(68)

Interest expense, net

(569)

(568)

(1,727)

(1,782)

Gain on debt forgiveness

3,014

Other income, net

4,209

4,209

Non-operating gain (loss), net

(605)

3,694

1,115

2,359

Loss before income tax (provision) benefit

(3,262)

27

(10,886)

(10,638)

Income tax (provision) benefit

(14)

(15)

7

(49)

Net income (loss)

(3,276)

12

(10,879)

(10,687)

Other comprehensive loss items:

Foreign currency translation adjustments

(90)

111

(173)

167

Comprehensive income (loss)

$

(3,366)

$

123

$

(11,052)

$

(10,520)

Net income (loss)

$

(3,276)

$

12

$

(10,879)

$

(10,687)

Deemed dividend on convertible preferred stock

(9)

(17,378)

(546)

(17,378)

Net loss attributable to common stockholders

$

(3,285)

$

(17,366)

$

(11,425)

$

(28,065)

Net loss per share attributable to common stockholders:

Basic

$

(0.02)

$

(0.21)

$

(0.08)

$

(0.56)

Diluted

$

(0.02)

$

(0.21)

$

(0.08)

$

(0.56)

Shares used in the calculation of net loss per share:

Basic

151,941

81,341

145,809

50,366

Diluted

151,941

81,341

145,809

50,366

BIOLASE, INC.

CONSOLIDATED BALANCE SHEETS

(Unaudited, in thousands, except per share data)

September 30,

December 31,

2021

2020

ASSETS

Current assets:

Cash and cash equivalents

$

33,385

$

17,564

Restricted cash

204

312

Accounts receivable, less allowance of $2,871 and $4,017 as of September 30, 2021 and
December 31, 2020, respectively

3,637

3,059

Inventory

14,062

11,157

Prepaid expenses and other current assets

1,366

3,018

Total current assets

52,654

35,110

Property, plant, and equipment, net

889

782

Goodwill

2,926

2,926

Right of use asset

1,823

1,976

Other assets

222

231

Total assets

$

58,514

$

41,025

LIABILITIES, REDEEMABLE PREFERRED STOCK AND
STOCKHOLDERS’ EQUITY

Current liabilities:

Accounts payable

$

3,597

$

2,651

Accrued liabilities

6,182

6,667

Deferred revenue, current portion

2,278

1,905

Term loan, net of discount

1,400

Total current liabilities

13,457

11,223

Deferred revenue

294

374

Warranty accrual

472

384

Non current term loans, net of discount

12,114

16,186

Non current operating lease liability

1,557

1,774

Other liabilities

298

1,056

Total liabilities

28,192

30,997

Stockholders’ equity:

Series F Preferred stock, par value $0.001 per share

34

118

Common stock, par value $0.001 per share

153

98

Additional paid-in capital

292,948

261,573

Accumulated other comprehensive loss

(558)

(385)

Accumulated deficit

(262,255)

(251,376)

Total stockholders’ equity

30,322

10,028

Total liabilities, redeemable preferred stock and stockholders’ equity

$

58,514

$

41,025

BIOLASE, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited, in thousands)

Nine Months Ended

September 30,

2021

2020

Cash Flows from Operating Activities:

Net loss

$

(10,879)

$

(10,687)

Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities:

Depreciation and amortization

281

527

Provision for bad debts

(162)

1,263

Provision for sales returns

87

Inventory write-offs and disposals

(117)

Amortization of discount on lines of credit

126

123

Amortization of debt issuance costs

290

240

Patent litigation mark-to-market

190

Change in fair value of warrants

(5,850)

Issuance of restricted shares

164

Issuance costs for common stock warrants

1,640

Stock-based compensation

1,488

2,367

Gain on debt forgiveness

(3,014)

Changes in operating assets and liabilities:

Accounts receivable

(417)

4,017

Inventory

(2,788)

(1,597)

Prepaid expenses and other current assets

235

430

Accounts payable and accrued liabilities

705

(3,445)

Deferred revenue

292

(562)

Net cash and cash equivalents used in operating activities

(13,606)

(11,447)

Cash Flows from Investing Activities:

Purchases of property, plant, and equipment

(396)

(78)

Net cash and cash equivalents used in investing activities

(396)

(78)

Cash Flows from Financing Activities:

Proceeds from the sale of common stock

13,291

6,912

Proceeds from the sale of common stock warrants

15,300

Proceeds from the issuance of Series F Convertible Preferred Stock

2,700

Payments of equity offering costs

(6)

(1,281)

Payment of July 2020 Warrant issuance costs

(1,640)

Borrowings on other long-term loans

3,140

Principal payment on loan

(700)

Borrowings on credit facility

3,000

Repayment of credit facility

(3,000)

Proceeds from the exercise of common stock warrants

16,560

46

Payment of debt issuance costs

(25)

(75)

Proceeds from exercise of stock options

66

Net cash and cash equivalents provided by financing activities

29,886

24,402

Effect of exchange rate changes

(171)

181

Increase in cash, cash equivalents and restricted cash

15,713

13,058

Cash, cash equivalents and restricted cash, beginning of period

17,876

6,101

Cash, cash equivalents and restricted cash, end of period

$

33,589

$

19,159

Supplemental cash flow disclosure:

Cash paid for interest

$

1,328

$

1,438

Cash received for interest

$

44

$

Cash paid for income taxes

$

154

$

21

Cash paid for operating leases

$

185

$

417

Non-cash settlement of liability

$

510

$

151

Non-cash right-of-use assets obtained in exchange for lease obligation

$

48

$

2,037

Deemed dividend on preferred stock

$

546

$

17,378

Warrants issued in connection with debt instruments

$

$

67

Non-GAAP Financial Measures

In addition to the financial information prepared in conformity with generally accepted accounting principles in the U.S. (“GAAP”), this press release includes certain historical non-GAAP financial information. Management believes that these non-GAAP financial measures assist investors in making comparisons of period-to-period operating results and that, in some respects, these non-GAAP financial measures are more indicative of the Company’s ongoing core operating performance than their GAAP equivalents.

Adjusted EBITDA is defined as net income (loss) before interest, taxes, depreciation and amortization, loss on patent litigation settlement, stock-based and other non-cash compensation, debt forgiveness, other net income, and allowance for doubtful accounts. Management uses Adjusted EBITDA in its evaluation of the Company’s core results of operations and trends between fiscal periods and believes that these measures are important components of its internal performance measurement process. Therefore, investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. Further, the non-GAAP financial measures presented by the Company may be different from similarly named non-GAAP financial measures used by other companies.

BIOLASE, INC.

Reconciliation of GAAP Net Loss to Adjusted EBITDA and

GAAP Net Loss Per Share to Adjusted EBITDA Per Share

(Unaudited, in thousands, except per share data)

Three Months Ended

Nine Months Ended

September 30,

September 30,

2021

2020

2021

2020

GAAP net loss attributable to common stockholders

$

(3,285)

$

(17,366)

$

(11,425)

$

(28,065)

Deemed dividend on convertible preferred stock

9

17,378

546

17,378

GAAP net income (loss)

$

(3,276)

$

12

$

(10,879)

$

(10,687)

Adjustments:

Interest expense, net

569

568

1,727

1,782

Income tax provision (benefit)

14

15

(7)

49

Depreciation and amortization

101

46

281

527

Change in allowance for doubtful accounts

(83)

256

(162)

1,263

Loss on patent litigation settlement

29

190

Stock-based and other non-cash compensation

192

847

1,488

2,367

Gain on debt forgiveness

(3,014)

Other (income) expense, net

(4,209)

(4,209)

Adjusted EBITDA

$

(2,454)

$

(2,465)

$

(10,376)

$

(8,908)

GAAP net loss attributable to common stockholders

per share, basic and diluted

$

(0.02)

$

(0.21)

$

(0.08)

$

(0.56)

Deemed dividend on convertible preferred stock

0.21

0.35

GAAP net loss per share, basic and diluted

$

(0.02)

$

$

(0.08)

$

(0.21)

Adjustments:

Interest expense, net

0.01

0.01

0.04

Income tax provision (benefit)

Depreciation and amortization

0.01

Change in allowance for doubtful accounts

0.03

Loss on patent litigation settlement

Stock-based and other non-cash compensation

0.01

0.01

0.05

Gain on debt forgiveness

(0.02)

Other (income) expense, net

(0.05)

(0.10)

Adjusted EBITDA per share, basic and diluted

$

(0.02)

$

(0.03)

$

(0.08)

$

(0.18)

Cision

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/biolase-reports-46-revenue-growth-in-2021-third-quarter-demand-for-dental-lasers-from-new-customers-remains-high-and-continues-to-fuel-growth-301421567.html

SOURCE BIOLASE, Inc.